Bicara Therapeutics (BCAX) Non Operating Income (2023 - 2026)

Bicara Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Non Operating Income fell 18.57% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 1.27% increase from a year earlier, with the FY2025 full-year figure at $17.9 million, up 22.56% from the prior year.
• Non Operating Income improved to $4.1 million in Q1 2026 per BCAX's latest filing, from $3.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at $5.9 million in Q4 2024 and bottomed at -$13.3 million in Q3 2023.
• The 4-year median for Non Operating Income is $3.8 million (2025), against an average of $2.2 million.
• Across the five-year window, Non Operating Income soared 368.53% in 2024 and tumbled 35.41% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.3 million in 2023, then soared by 368.53% to $5.9 million in 2024, then tumbled by 35.41% to $3.8 million in 2025, then grew by 7.76% to $4.1 million in 2026.
• Per Business Quant, the three latest BCAX Non Operating Income figures stand at $4.1 million (Q1 2026), $3.8 million (Q4 2025), and $4.4 million (Q3 2025).